Ok.
All the best for your investing journey!
Hello drrakesh,
the newer patent was a mere extension sought by Pfizer. Refer this article for the full context of this.
Judge Allen invalidated the reissue patent for the same reason the Federal Circuit invalidated the original one — “double-patenting.” Pfizer had argued that, as part of the reissue, it had reclassified the patent in a way that made it eligible for a safe harbor that protects patents from invalidation on “double-patenting” grounds. But Judge Allen found that the reissuance process could not be used for that purpose, and the flaw was therefore “not correctable.”
Thanks Ankit.
As per this news article, pegs the generic market for Celebrex at $400 million.
"Lupin currently holds 14 per cent market share for Celebrex and expect $58 million sales from the drug with a 15 per cent market share"
However, off late, there are reports of adverse effects from generic Celebrex, read here. So it is debatable how easy it will be for Alembic to garner market share.
Hi Anil,
IMHO the link below can provide us insight that supply is not a concern yet as stock exists after taking into account local supply and exports.
http://www.supima.com/view-reports/supply-and-use/
The winds are favouring the Indian Textile industry and also factories in China are lowering their production due to high overhead costs and hence demand for raw material would decrease in China. The excess raw material can then make way to India.
I was zapped for a moment and then I realized what I had done.
Oh my bad - if you notice carefully, the first section and last section contain inputs that I had solicited from industry experts. For each of the companies I track, I keep a master document containing everything I can lay my hands on the company. In ambika's case, I had copied your blog's inputs verbatim into the word document which was succeeded by inputs from a reputed textile entrepreneur in coimbatore.
I just copied the entire document into VP thread without bothering to remove your blog in the middle. I had no intention of claiming credit or passing off your work as my own.
apologies and sorry about that. Uploading the word doc I maintain on ambika as is - which incidentally has another positive ref check I had done.
ambika.docx (81.0 KB)
As per this http://www.piindustries.com/sites/default/files/As%20Demand%20for%20Faster_1.pdf PI works with Syngenta.
You can also find other names in there.
For its domestic input business, the company licenses and registers products it
considers to have major potential in India from Japanese players such as Kumiai, Mitsui and Nichino, and markets them on an exclusive basis. Additionally, PI works with multinationals that already have a presence in India, such as Bayer CropScience, Syngenta and BASF, and co-markets their products under the PI brand.
MOTILAL OSWAL the Morgan Stanley of India has initiated coverage and said its a 100x stock in its report, after Auctus integration and JV with foreigners and moving into high RoE businesses, they will become big and there will be value migration, buy and buy
Adi Finechem exports DEODORIZER DISTILLATE (MIXED TOCOPHEROLCONCENTRATE) WITH 08.35% TOCOPHEROLS.
When I check export data it shows declining trend. Adi might be loosing market or demand for there product might be decreasing
I don't know if PI discloses client dealings. In general, absence of merger is actually a good thing for PI since both companies will pursue R&D efforts separately.
Thanks Sam for your effort! looks promising
Disc: invested and added in the current dip
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!